LYEL · Lyell Immunopharma, Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $27K | $36K | $61K | $130K | $84.68M | $10.65M | $7.76M | $657K | |
| $156.5M | $158.68M | $171.6M | $182.95M | $159.19M | $138.69M | $182.24M | $63.6M | |
| $40.43M | $45.14M | $52.04M | $66.98M | $117.31M | $89.06M | $46.88M | $39.15M | |
| $9.52M | $11.54M | $19.63M | $20.25M | $18.02M | $13.62M | $4.29M | $1.26M | |
| — | — | — | $5.52M | — | — | — | — | |
| $256.52M | $269.44M | $358.82M | $247.14M | $271.74M | $225.43M | $219.69M | $102.75M | |
| -$256.5M | -$269.4M | -$358.76M | -$247.01M | -$187.06M | -$214.78M | -$211.94M | -$102.09M | |
| — | -748344.44% | -588122.95% | -190006.15% | -220.89% | -2016.68% | -2732.56% | -15538.66% | |
| -$246.98M | -$257.87M | -$339.12M | -$226.76M | -$169.04M | -$201.15M | -$207.64M | -$100.83M | |
| $8.02M | -$5.04M | $15.76M | $12.38M | $3.94M | -$35.44M | $7.47M | -$27.29M | |
| — | $0 | — | — | — | — | — | — | |
| -$248.48M | -$274.45M | -$342.99M | -$234.63M | -$183.12M | -$250.22M | -$204.47M | -$129.38M | |
| — | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% | -2636.31% | -19692.09% | |
| — | — | — | — | -$183.12M | -$250.22M | -$208.05M | -$130.52M | |
| -$248.69M | -$274.5M | -$342.61M | -$227.13M | -$189.09M | -$252.1M | -$204.67M | -$128.92M | |
| USD/shares | -$12.65 | -$16.06 | -$26.23 | -$18.70 | -$14.80 | -$36.80 | -$313.80 | -$480.80 |
| USD/shares | -$12.65 | -$16.06 | -$26.23 | -$18.70 | -$14.80 | -$36.80 | -$313.80 | -$480.80 |
| shares | — | 17.09M | 13.07M | 12.55M | 12.35M | 6.8M | 662.9K | 271.45 |
| shares | — | 17.09M | 13.07M | 12.55M | 12.35M | 6.8M | 662.9K | 271.45 |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2022: $11.99M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 319 similar-size Biotechnology companies (of 536 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $36,000 | $61,000 | $130,000 | $84,683,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Reportable Segment | -$358,755,000 | -$247,008,000 | -$187,058,000 |
Operating Margin by Segment (%)
| Component | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Reportable Segment | -588123% | -190006.2% | -220.9% |